Literature DB >> 17238157

Allosteric modifiers of neuronal nicotinic acetylcholine receptors: new methods, new opportunities.

Ruin Moaddel1, Krzysztof Jozwiak, Irving W Wainer.   

Abstract

Allosteric, non-competitive inhibitors (NCIs) of neuronal nicotinic acetylcholine receptors (nAChRs) have been shown to produce a wide variety of clinically relevant responses. Many of the observed effects are desired as the nAChR is the therapeutic target, while others are undesired consequences due to off-target binding at the nAChR. Thus, the determination of whether or not a lead drug candidate is an NCI should play an important role in drug discovery programs. However, the current experimental techniques used to identify NCIs are challenging, expensive, and time consuming. This review focuses on an alternative approach to the investigation of interactions between test compounds and nAChRs based upon liquid chromatographic stationary phases containing cellular fragments from cell lines expressing nAChRs. The development and validation of these phases as well as their use in drug discovery and pharmacophore modeling are discussed. (c) 2006 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17238157     DOI: 10.1002/med.20091

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  25 in total

1.  Nicotinic acetylcholine receptor transmembrane mutations convert ivermectin from a positive to a negative allosteric modulator.

Authors:  Toby Collins; Neil S Millar
Journal:  Mol Pharmacol       Date:  2010-05-12       Impact factor: 4.436

2.  Negative allosteric modulators that target human alpha4beta2 neuronal nicotinic receptors.

Authors:  Brandon J Henderson; Ryan E Pavlovicz; Jerad D Allen; Tatiana F González-Cestari; Crina M Orac; Andrew B Bonnell; Michael X Zhu; R Thomas Boyd; Chenglong Li; Stephen C Bergmeier; Dennis B McKay
Journal:  J Pharmacol Exp Ther       Date:  2010-06-15       Impact factor: 4.030

3.  Screening of tobacco smoke condensate for nicotinic acetylcholine receptor ligands using cellular membrane affinity chromatography columns and missing peak chromatography.

Authors:  Alexandre Maciuk; Ruin Moaddel; Jun Haginaka; Irving W Wainer
Journal:  J Pharm Biomed Anal       Date:  2007-11-26       Impact factor: 3.935

4.  Interaction of ibogaine with human alpha3beta4-nicotinic acetylcholine receptors in different conformational states.

Authors:  Hugo R Arias; Avraham Rosenberg; Katarzyna M Targowska-Duda; Dominik Feuerbach; Xiao Juan Yuan; Krzysztof Jozwiak; Ruin Moaddel; Irving W Wainer
Journal:  Int J Biochem Cell Biol       Date:  2010-09       Impact factor: 5.085

Review 5.  The development and characterization of protein-based stationary phases for studying drug-protein and protein-protein interactions.

Authors:  Mitesh Sanghvi; Ruin Moaddel; Irving W Wainer
Journal:  J Chromatogr A       Date:  2011-05-27       Impact factor: 4.759

Review 6.  Determination and modelling of stereoselective interactions of ligands with drug transporters: a key dimension in the understanding of drug disposition.

Authors:  P Bhatia; M Kolinski; R Moaddel; K Jozwiak; I W Wainer
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

7.  The preparation and development of cellular membrane affinity chromatography columns.

Authors:  Ruin Moaddel; Irving W Wainer
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

8.  Interaction of cepharanthine with immobilized heat shock protein 90α (Hsp90α) and screening of Hsp90α inhibitors.

Authors:  Jun Haginaka; Tomoko Kitabatake; Iyo Hirose; Hisami Matsunaga; Ruin Moaddel
Journal:  Anal Biochem       Date:  2012-12-03       Impact factor: 3.365

Review 9.  Comparison of analytical techniques for the identification of bioactive compounds from natural products.

Authors:  Łukasz Cieśla; Ruin Moaddel
Journal:  Nat Prod Rep       Date:  2016-07-01       Impact factor: 13.423

10.  In vivo pharmacological interactions between a type II positive allosteric modulator of α7 nicotinic ACh receptors and nicotinic agonists in a murine tonic pain model.

Authors:  K Freitas; S S Negus; F I Carroll; M I Damaj
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.